LEGISLATIVE FISCAL ESTIMATE
[Second Reprint]
ASSEMBLY, No. 1747
STATE OF NEW JERSEY
220th LEGISLATURE
DATED: JUNE 9, 2022
SUMMARY
Synopsis: Establishes Prescription Drug Affordability Board; appropriates $1
million.
Type of Impact: Annual increase in State expenditures from the General Fund.
Agencies Affected: Department of Law and Public Safety; Department of Human
Services; Department of Children and Families; Department of
Corrections; Department of the Treasury; University Hospital; Local
governments.
Office of Legislative Services Estimate
Fiscal Impact Year 1 Year 2 Year 3
State Cost Increase Up to $1 million Indeterminate Indeterminate
 The Office of Legislative Services (OLS) finds that the bill will increase State expenditures by
up to $1 million in FY 2022 for salaries, benefits, and one-time start-up costs related to the
newly created Prescription Drug Affordability Board. Thereafter, the State will incur
indeterminate annual operating costs for the ongoing administrative expenses of the board and
any contracts for essential services entered into by the board with third parties. The bill
appropriates $1 million to support the activities of the board in FY 2022.
 The State and local governments could potentially realize indeterminate annual expenditure
savings to the extent that future legislation implementing the board’s plan of action reduces
prescription drug costs.
BILL DESCRIPTION
This bill establishes the Prescription Drug Affordability board in, but not of, the Department
of Law and Public Safety, which is charged with studying the need for legislative action and State
policies to reduce the costs paid by the State and local governments, health benefits plans, health
Office of Legislative Services Legislative Budget and Finance Office
State House Annex Phone (609) 847-3105
P.O. Box 068 Fax (609) 777-2442
Trenton, New Jersey 08625 www.njleg.state.nj.us
 FE to A1747 [2R]
2
care providers, pharmacies, and other stakeholders in the State health care system for prescription
drug products.
The bill also establishes the Prescription Drug Affordability Stakeholder Council, which is to
provide stakeholder input to assist the board in making decisions.
The bill requires the board to conduct a study of the pharmaceutical distribution and payment
system in the State, as well as policy options implemented by other states and countries to lower
the list price of pharmaceutical drug products, including but not limited to: establishing upper
payment limits; using a closed formulary; allowing importation of pharmaceutical drug products
from other countries; and implementing a bulk purchasing process.
If the board determines that it is in the best interest of the State to develop a process to establish
upper payment limits or allow importation from other countries of certain prescription drug
products, the board, in conjunction with the council, is required to draft a plan of action for
implementing such a process. The board may recommend both establishing upper payment limits
and allowing importation of pharmaceutical drug products from other countries. Any
recommended upper payment limit will apply to prescription drug products purchased by, or on
behalf of, State and local government entities, programs, and organizations.
The board is to submit its action plan to the Legislature for approval no later than 24 months
after the effective date of the bill. The plan will be deemed rejected unless legislation
implementing the plan is adopted within 90 days after the date the plan is submitted. The board
will have no authority to establish upper payment limits or permit importations from other
countries of prescription drug products unless the action plan is approved through the adoption of
implementing legislation.
The board is also authorized to conduct hearings concerning potential violations of the
requirements established under the bill, refer non-compliance matters to the Attorney General, and
enter into contracts with qualified, independent third parties for any service necessary to carry out
its powers and duties.
The bill furthermore authorizes the chair of the board to hire an executive director, general
counsel, and staff, and to develop a five-year budget and staffing plan that will be subject to
approval by the board as a whole. The executive director, general counsel, and board staff are to
receive a salary. Board members are entitled to compensation as may be approved under the State
budget, and are entitled to reimbursement for expenses reasonably incurred in the performance of
their official duties.
The bill appropriates $1 million from the General Fund to the Prescription Drug Affordability
Board in FY 2022.
FISCAL ANALYSIS
EXECUTIVE BRANCH
None received.
OFFICE OF LEGISLATIVE SERVICES
The OLS finds that the bill will increase State expenditures by up to $1 million in FY 2022 for
salaries, fringe benefits, and start-up costs related to the newly created Prescription Drug
Affordability Board. Thereafter, the State will incur indeterminate annual operating costs for the
ongoing administrative expenses of the board and any contracts for essential services entered into
by the board with third parties. The bill specifies that the chair of the board is to hire an executive
 FE to A1747 [2R]
3
director, general counsel, and other staff to support the board’s operations, as outlined in the five-
year budget and staffing plan developed by the chair. The OLS cannot project the composition of
the board’s staff and any compensation paid to them or to certain board members, but the bill
appropriates $1 million to support the activities of the board in FY 2022. The bill additionally
directs the Legislature to appropriate $1 million annually for the board’s activities in future fiscal
years. However, legislative language specifying future amounts of appropriations does not
guarantee future funding levels for the board’s activities.
The OLS further finds that the State and local governments could potentially realize
indeterminate annual expenditure savings to the extent that future legislation implementing the
board’s plan of action reduces prescription drug costs provided through the State Medicaid
program, commonly known as NJ FamilyCare, the State Health Benefits Program, the School
Employees’ Health Benefits Program, the Pharmaceutical Assistance to the Aged and Disabled
program, the Senior Gold Prescription Discount Program, and the Department of Corrections.
Prescription drug prices may also potentially be reduced for University Hospital, an independent
non-profit legal entity that is an instrumentality of the State, as well as for local government entities
that purchase or pay for prescription drug products or operate nursing homes. The magnitude and
timing of these cost savings for the State and local government entities cannot be reliably estimated
at this time, however, as it is unknown when the board will submit its action plan to the Legislature,
what its recommendations will include, and when any enabling legislation will be implemented.
Section: Human Services
Analyst: Anne Hunt Cappabianca
Associate Fiscal Analyst
Approved: Thomas Koenig
Legislative Budget and Finance Officer
This legislative fiscal estimate has been produced by the Office of Legislative Services due to the
failure of the Executive Branch to respond to our request for a fiscal note.
This fiscal estimate has been prepared pursuant to P.L.1980, c.67 (C.52:13B-6 et seq.).